Skip to main
  1. Stocks
  2. Candel Therapeutics
  3. Forecast
CADL

Candel Therapeutics (CADL) Stock Forecast & Price Target

Candel Therapeutics (CADL) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Candel Therapeutics is viewed favorably because CAN-2409’s clinical profile remains compelling, with Phase 3 PrTK03 showing a 39% reduction in prostate cancer recurrence or prostate cancer-specific death versus placebo after a median 58 months of follow-up (n=745, HR 0.61, p=0.0031), plus supportive secondary and exploratory endpoint trends. That efficacy backdrop, combined with an intact Special Protocol Assessment and a BLA submission targeted for 4Q26, supports confidence in regulatory execution even as assay validation and CMC readiness create some timing and financing risk. Beyond prostate cancer, the first site activation for the global Phase 3 AURORA study in NSCLC and prior Phase 2a survival signals reinforce the case that its off-the-shelf viral immunotherapy platform could drive a multi-indication commercial opportunity.

Bears say

Candel Therapeutics is facing a meaningful setback because its expected CAN-2409 BLA submission slipped from 4Q26 to mid-2027 after the infectious-unit titer assay failed validation due to excessive variability, including between operators. Although process validation for drug substance and drug product has been executed and batches remain consistent, the filing still depends on resolving the assay, completing comparability and CMC work, and potentially other Tier 1 assay steps that are not yet fully finished. The delay pushes revenue and cash generation further out, while clinical, regulatory, commercial, competitive, and financing risks remain elevated, justifying the more cautious outlook.

Candel Therapeutics (CADL) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Candel Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Candel Therapeutics (CADL) Analyst Forecast & Price Prediction

Get the latest Candel Therapeutics (CADL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Candel Therapeutics (CADL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Candel Therapeutics (CADL) Forecast

Analysts have given Candel Therapeutics (CADL) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Candel Therapeutics (CADL) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Candel Therapeutics (CADL)


Candel Therapeutics (CADL) Analyst Forecast & Price Prediction

Get the latest Candel Therapeutics (CADL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Candel Therapeutics (CADL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CADL stock data and trends